Dr. Jose A. Karam

Dr. Jose A. Karam

Speech Title: The Role of Cytoreductive Nephrectomy in 2020

Sub-specialty Areas:

Urologic Oncology; Kidney Cancer; Testicular Cancer; Adrenal Cancer; Surgery (open, laparoscopic, robotic) for advanced Kidney Cancer; Integration of Targeted Therapy and Surgery in Kidney Cancer Care; Sarcomatoid Kidney Cancer; Salvage and Reoperative Surgery; Postchemotherapy RPLND.


Dr. Karam is an Associate Professor in the Department of Urology and Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is certified by the American Board of Urology, and provides surgical care for men and women diagnosed with urologic malignancies, with a particular interest in renal, testicular and adrenal tumors.

Dr. Karam received his bachelor’s degree in Biology with Distinction and earned his medical degree with Distinction from the American University of Beirut. He completed a postdoctoral research fellowship in Tumor Biology in the Department of Urology at the University of Texas Southwestern Medical Center at Dallas, then completed Urology residency at the University of Texas Southwestern Medical Center at Dallas, followed by a two-year Urologic Oncology Fellowship in the Department of Urology at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Karam’s primary clinical and research interest is renal cell carcinoma. He performs open surgery, laparoscopic surgery, as well as robotic surgery, individually tailored for the needs of patients with cancers of the kidney, testis and adrenal, with a special interest in surgery for locally advanced and locally recurrent disease. Dr. Karam has a research interest in integration of targeted therapy with surgery, sarcomatoid renal cell carcinoma, rare kidney cancer histologies including renal medullary carcinoma, mouse models of renal cell carcinoma and molecular markers. In collaboration with colleagues from urology and genitourinary medical oncology, he is also involved in clinical trials investigating systemic therapy in the neoadjuvant/presurgical and adjuvant settings. Dr. Karam has authored more than 200 articles in urologic oncology, including original research, book chapters, reviews, and invited editorials.

Dr. Karam is a member of the American Urological Association, the Society of Urologic Oncology, the American Society of Clinical Oncology, the American College of Surgeons, and the American Association for Cancer Research. He serves as a reviewer for over 20 journals, including Lancet Oncology, New England Journal of Medicine, JAMA Oncology, Cancer, Journal of Urology, European Urology, Urologic Oncology, BJU International, among others. Dr. Karam is on the Editorial Boards of Cancer, BJU International, Clinical Genitourinary Cancer, European Urology Oncology, and serves as Section Editor (Urologic Oncology) for Annals of Surgical Oncology, and Associate Editor for Frontiers in Oncology (Genitourinary Oncology). Dr. Karam is also a member of the American Urological Association Testicular Cancer Guideline Panel.